Rationale for the prevention of syncope trial IV: assessment of midodrine
Authors:
- 19 May 2012
- journal article
- research article
- Published by Springer Nature in Clinical Autonomic Research
- Vol. 22 (6) , 275-280
Abstract
Background Vasovagal syncope is a common problem associated with a poor quality of life, which improves when the frequency of syncope is reduced. Effective pharmacological therapies for vasovagal syncope have been elusive. Midodrine is a pro-drug whose primary metabolite is an alpha-1 adrenoreceptor agonist. A few studies have suggested that it may be beneficial in syncope, but all have had significant methodological limitations. A placebo-controlled clinical trial of midodrine for the prevention of vasovagal syncope is needed. Structure of study The prevention of syncope trial IV (POST 4) is a multicenter, international, randomized, placebo-controlled study of midodrine in the prevention of vasovagal syncope. The primary end point is the time to first recurrence of syncope. Patients will be randomized 1:1 to receive midodrine 10–30 mg/day or matching placebo, and followed for 1 year. Secondary end points include syncope frequency, presyncope, and quality of life. Primary analysis will be performed with an intention-to-treat approach, with a secondary on-treatment analysis. Power calculations A total sample size of 112, split equally between the two groups, achieves 85 % power to detect a 50 % relative risk reduction when the event rates are 55 and 27.5 % in the placebo and midodrine arms. Allowing for 20 % dropout, we propose to enroll 140 patients. Registration POST 4 is registered with http://www.clinicaltrials.gov (NCT01456481). Implications This study will be the first adequately powered trial to determine whether midodrine is effective in preventing vasovagal syncope. If it is effective, then midodrine may become the first-line pharmacological therapy for this condition.Keywords
This publication has 33 references indexed in Scilit:
- The development and preliminary validation of a scale measuring the impact of syncope on quality of lifeEP Europace, 2009
- Design and Use of a Quantitative Scale for Measuring PresyncopeJournal of Cardiovascular Electrophysiology, 2009
- Pharmacokinetic and pharmacodynamic effects of midodrine on blood pressure, the autonomic nervous system, and plasma natriuretic peptides: a prospective, randomized, single-blind, two-period, crossover, placebo-controlled studyClinical Therapeutics, 2008
- The efficacy of midodrine hydrochloride in the treatment of children with vasovagal syncopeThe Journal of Pediatrics, 2006
- The Second Prevention of Syncope Trial (POST II)—a randomized clinical trial of fludrocortisone for the prevention of neurally mediated syncope: Rationale and study designAmerican Heart Journal, 2006
- Diagnostic criteria for vasovagal syncope based on a quantitative historyEuropean Heart Journal, 2005
- Direct medical costs of syncope-related hospitalizations in the United StatesThe American Journal of Cardiology, 2005
- Relation of Postural Vasovagal Syncope to Splanchnic Hypervolemia in AdolescentsCirculation, 2004
- Sympathetic and baroreceptor reflex function in neurally mediated syncope evoked by tilt.Journal of Clinical Investigation, 1997
- Quantification of midodrine and its active metabolite in plasma using a high performance liquid chromatography column switching techniqueBiomedical Chromatography, 1989